Off-label meds: normal, legal, worth asking about

Every medicine comes with a license: a list of the conditions, ages and doses it was tested and approved for. When a doctor prescribes it for something else, that is called off-label. It sounds shady, but it is legal, common and often sensible: in ADHD and sleep medicine it happens every day. What matters is the evidence behind each use, which can be anything from big trials to a few hopeful case reports.

Key points

• Off-label means “outside the license”, not illegal and not experimental. Doctors may prescribe this way; companies may not advertise it.
• The prescriber carries more responsibility. UK regulators ask them to be satisfied there is enough evidence or experience, and to explain the choice to you.
• The same use can be licensed in one country and off-label in another. Modafinil for shift work is licensed in the US and off-label in the UK and EU.
• You can ask about it. If the usual options did not work for you, an off-label medicine may be worth discussing with your prescriber.

What “licensed” and “off-label” really mean

Before a medicine goes on sale, its maker has to show a regulator that it works and is safe enough for a defined use. The approval covers what the company tested: the condition, the age group, the dose and how it is taken. Those details go into the official product information (the US prescribing label, or the summary of product characteristics in the UK and EU).

Off-label use is anything outside those terms. The US Food and Drug Administration lists three kinds: a condition the drug is not approved for, a different form (a capsule given as a liquid, for example) and a different dose. A different age group counts too.

The FDA’s position is that once a drug is approved, healthcare providers “generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient.” It adds the other half: in that case, the FDA “has not determined that the drug is safe and effective for the unapproved use.”

What regulators expect from the prescriber

The UK’s medicines regulator, the MHRA, says responsibility “may be greater” when a doctor prescribes off-label. Its advice to prescribers is to:

• be satisfied that the off-label use would serve you better than a licensed alternative;
• be satisfied that there is “a sufficient evidence base and/or experience of using the medicine to show its safety and efficacy”;
• take responsibility for the prescription and for your follow-up and monitoring;
• record what was prescribed and why, and give you enough information about the treatment, including its known serious or common side effects.

NICE, which writes the treatment guidelines for England, marks off-label uses inside its own ADHD guideline. Several of its standard recommendations are off-label, which shows how routine this is.

Off-label uses in ADHD and sleep medicine

The table shows where each medicine on this site is licensed. Anything outside these columns is off-label in that country.

Some examples of how far apart the evidence can sit:

• Strong evidence, still off-label: lisdexamfetamine for binge eating in the UK. Randomized trials in adults led the US to approve it; the UK license does not include it.
• Mixed evidence: modafinil for ADHD in adults. Small trials found some benefit, and the largest recent comparison of adult ADHD treatments found good evidence only for stimulants and atomoxetine. The details are on the modafinil page.
• Negative evidence: modafinil for fatigue in multiple sclerosis. It is commonly prescribed for this, but a 2021 crossover trial in 136 patients found it no better than placebo, with more side effects.

Why doctors prescribe off-label

The FDA gives two common reasons: no approved medicine exists for your condition, or the approved ones did not help you. In ADHD a third reason comes up often: you cannot take a stimulant, because of side effects, a heart condition or a past problem with misuse, or because stimulants are hard to get where you live. Non-stimulants and wakefulness medicines are then the next options to discuss, licensed or not.

Off-label prescribing has costs. Insurers may refuse to pay for a use the label does not cover, the leaflet in the box will describe a different condition, and fewer people have taken the medicine your way, so less is known about its rarer side effects.

Questions to ask your prescriber

Take this to your appointment

Seven questions the FDA suggests

When a doctor proposes an off-label use, ask:

1. What is this medicine approved for?
2. Are there approved medicines or therapies for my condition?
3. What studies support using it this way?
4. Is it likely to work better for me than an approved treatment?
5. What are the benefits and risks for me?
6. Will my insurance cover it?
7. Are there clinical trials I could join?

Then agree on three more: how you will both judge whether it is working, how long to try it before deciding, and what monitoring you will need.

How this site covers off-label uses

Each page about an off-label use starts with where that use is and is not approved, then gives the trial results with their size and quality, then patient reports gathered from Reddit, clearly marked as anecdotes. Negative results get the same space as positive ones. Nothing here recommends an off-label use: only a prescriber who knows you can decide that one is right for you.

Sources

Checked 17 October 2026.

1. Understanding unapproved use of approved drugs "off label" — US Food and Drug Administration
2. Off-label or unlicensed use of medicines: prescribers’ responsibilities — MHRA Drug Safety Update (UK)
3. Attention deficit hyperactivity disorder: diagnosis and management (NG87), recommendations 1.7.7 to 1.7.17 — NICE (UK)
4. Questions and answers on the review of medicines containing modafinil (EMA/725532/2010) — European Medicines Agency
5. Strattera (atomoxetine) prescribing information, section 1 — DailyMed (US National Library of Medicine)
6. Provigil (modafinil) prescribing information, section 1 — DailyMed
7. Vyvanse (lisdexamfetamine) prescribing information, section 1 — DailyMed
8. Intuniv (guanfacine extended-release) prescribing information — DailyMed
9. Qelbree (viloxazine extended-release) prescribing information, section 1 — DailyMed
10. Wellbutrin SR (bupropion) prescribing information, section 1 — DailyMed
11. Lisdexamfetamine for adults with moderate to severe binge-eating disorder (McElroy et al., 2015) — JAMA Psychiatry
12. Amantadine, modafinil and methylphenidate for fatigue in multiple sclerosis (TRIUMPHANT-MS, Nourbakhsh et al., 2021) — The Lancet Neurology
13. Interventions for ADHD in adults, systematic review and component network meta-analysis (Ostinelli et al., 2025) — The Lancet Psychiatry